-Cancer Outcomes (CO) Shared Resource The Cancer Outcomes (CO) Shared Resource is a new resource to support a large and highly productive group of cancer center faculty conducting population science big data research, including analyses of linked cancer registry/insurance claims datasets; epidemiologic cohort studies; registries; and other real-world clinical data sources. The CO provides three main services: 1) development and support of a North Carolina multi- payer linked dataset; 2) methodological consulting services for population science big data analyses; and 3) software/systems development for managing real-world clinical data. By collaborating with the North Carolina Central Cancer Registry and other data partners, this unique North Carolina dataset represents the entire state?s cancer population (>400,000 patients) as well as 5.5 million unique beneficiaries in Medicare, Medicaid, and private insurance plans. This rich and unprecedented state-level resource represents heterogeneous populations which are often not represented in clinical trials. This shared resource directly addresses the emerging need of population science to develop big data infrastructure and methods. Research supported by the CO can directly answer crucial questions in cancer care related to access, disparities, quality, technology diffusion, guideline adherence, and cost of cancer care. The differential impact of insurance coverage models and policy initiatives can also be evaluated at the population, provider, and patient levels. Through an interdisciplinary ?team science? approach, the Cancer Outcomes Shared Resource has developed novel data linkages, systems, and methods that allow researchers to better leverage the power of big data to improve population health. By partnering closely with computer scientists and research methodologists the CO team has developed extensive tools and web systems which make these big datasets interoperable and support the entire research lifecycle from hypothesis generation through manuscript publication. Supported by Cancer Center funds since its inception in 2012, this shared resource is already a highly used and successful resource: CO staff has worked with 36 faculty members, enabled publication of 41 manuscripts in peer- reviewed journals and nearly $10 million in funding from private and public sources external to UNC. Funds are proposed to support salary for key staff members and annual data updates

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016086-44
Application #
9834863
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-12-01
Budget End
2020-11-30
Support Year
44
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Brosnan, Evelyn M; Anders, Carey K (2018) Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies. Ann Transl Med 6:163
Valle, Carmina G; Queen, Tara L; Martin, Barbara A et al. (2018) Optimizing Tailored Communications for Health Risk Assessment: A Randomized Factorial Experiment of the Effects of Expectancy Priming, Autonomy Support, and Exemplification. J Med Internet Res 20:e63
Sun, Junjiang; Shao, Wenwei; Chen, Xiaojing et al. (2018) An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs. Mol Ther Methods Clin Dev 10:257-267
Wilczewski, Caralynn M; Hepperla, Austin J; Shimbo, Takashi et al. (2018) CHD4 and the NuRD complex directly control cardiac sarcomere formation. Proc Natl Acad Sci U S A 115:6727-6732
Waters, Andrew M; Der, Channing J (2018) KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harb Perspect Med 8:
Cai, Ling; Tsai, Yi-Hsuan; Wang, Ping et al. (2018) ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer. Mol Cell 72:341-354.e6
Moschos, Stergios J; Sullivan, Ryan J; Hwu, Wen-Jen et al. (2018) Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. JCI Insight 3:
Mirlekar, Bhalchandra; Michaud, Daniel; Searcy, Ryan et al. (2018) IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer. Cancer Immunol Res 6:1014-1024
Buist, Diana S M; Abraham, Linn; Lee, Christoph I et al. (2018) Breast Biopsy Intensity and Findings Following Breast Cancer Screening in Women With and Without a Personal History of Breast Cancer. JAMA Intern Med 178:458-468
Zhang, Jing; Wu, Tao; Simon, Jeremy et al. (2018) VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. Science 361:290-295

Showing the most recent 10 out of 1525 publications